Aurobindo Pharma is currently trading at Rs. 194.55, up by 1.55 points or 0.80% from its previous closing of Rs. 193.00 on the BSE.
The scrip opened at Rs. 194.00 and has touched a high and low of Rs. 195.35 and Rs. 192.55 respectively. So far 43,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 201.40 on 05-Dec-2012 and a 52 week low of Rs. 83.35 on 29-Dec-2011.
Last one week high and low of the scrip stood at Rs. 198.95 and Rs. 186.70 respectively. The current market cap of the company is Rs. 5,663 crore.
The promoters holding in the company stood at 54.76% while Institutions and Non-Institutions held 29.33% and 15.91% respectively.
Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Nafcillin for Injection USP, packaged in 1g and 2g vials and Nafcillin for Injection USP 10g/Vial Pharmacy Bulk Package. The products are ready for launch.
Nafcillin for Injection is a sterile semisynthetic penicillin (SSP) indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. It may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. These ANDAs have been approved out of Unit XII formulation facility in Hyderabad, India and will be marketed and sold by Aurobindo's US subsidiary AuroMedics Pharma LLC.
Aurobindo now has a total of 171 ANDA approvals (145 Final approvals including 2 from Aurolife Pharma LLC and 26 Tentative approvals) from USFDA.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1821.15 |
Dr. Reddys Lab | 1345.90 |
Cipla | 1482.65 |
Lupin | 2178.10 |
Zydus Lifesciences | 977.50 |
View more.. |